Navigation Links
As Risperdal Lawsuits Move Forward, Wright & Schulte LLC Learns of Bid to Keep Clinical Studies Sealed in Pennsylvania Risperdal Litigation
Date:12/11/2013

(PRWEB) December 11, 2013

Wright & Schulte LLC has learned that Johnson & Johnson has filed a motion in Risperdal lawsuits pending in Pennsylvania state court to keep sealed certain clinical studies pertaining to the antipsychotic drug. According to court documents filed in the Philadelphia Court of Common Pleas, the studies were originally sealed in 2011. In its November 26th motion, Johnson & Johnson urged the Court to allow the studies to stay sealed, as they were intended to be used by researchers and regulators, not the general public. (In Re: Risperdal Litigation, Case ID. 100300296)

The firm indicates that court records show more than 200 Risperdal lawsuits are pending in Pennsylvania, dozens of which were filed on behalf of alleged victims of gynecomastia, or male breast growth. Plaintiffs in these Risperdal gynecomastia lawsuits allege the use of the drug caused them to develop breasts so large that they have had to undergo liposuction or mastectomies to remove excess breast tissue. Even after undergoing breast reduction surgery, affected patients allegedly suffered psychological and emotional distress due to the development of gynecomastia. The complaints also accuse Johnson & Johnson of concealing the risk of male breast growth from patients and the medical community.

For more information on Risperdal lawsuits visit our website to stay connected to all the latest news.

Wright & Schulte LLC has also learned from a Bloomberg.com report of October 2012, Johnson & Johnson reached undisclosed settlements in five Risperdal gynecomastia lawsuits filed in the Pennsylvania litigation just before the cases went to trial. However, dozens of such claims remain unresolved. According to a motion filed on November 5th, plaintiffs in 77 other Risperdal gynecomastia lawsuits have asked the Court to enforce a settlement in their claims that Johnson & Johnson allegedly agreed to last January.
[Bloomberg.com/news/2012-10-04/johnson-johnson-agrees-to-settle-five-rispersal-suits.html, Bloomberg.com, October 10, 2012]

On November 4th, the U.S. Department of Justice reported that Johnson & Johnson had agreed to pay $2.2 billion to settle criminal and civil charges involving the off-label marketing of Risperdal and other drugs. The accord was one of the largest health care fraud settlements in U.S. history, the DOJ said. Among other things, federal prosecutors had charged that Risperdal was improperly marketed for use in children before being approved by the U.S. Food & Drug Administration for such purposes. They also alleged that the company concealed the risk of male breast growth.
[justice.gov/opa/pr/2013/November/13-ag-1170.html?source=email_rt_mc_body&app=n]

Victims of gynecomastia (male breast growth) allegedly associated with the use of Risperdal may be eligible to file their own Risperdal lawsuit. To learn more, or to arrange for a free legal consultation with an attorney at Wright & Schulte LLC, please visit yourlegalhelp.com.

About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Risperdal lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:
Wright & Schulte LLC
"A Leading Defective Drug Law Firm"
1-800-399-0795
http://www.yourlegalhelp.com

Read the full story at http://www.prweb.com/releases/2013/12/prweb11413623.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Parker Waichman LLP Commends Arkansas Attorney General for Backing Fine Against Johnson & Johnson over Risperdal Off-Label Marketing Allegations
2. The Consumer Justice Foundation Launches RisperdalLaw.com, an Informational Web Site Dealing with Alleged Risperdal Side Effects Including Gynecomastia
3. Bernstein Liebhard LLP Investigating Risperdal Lawsuits on Behalf of Victims of Male Breast Growth Allegedly Caused by Risperdal
4. New Risperdal Lawsuit Filed in Pennsylvania Litigation; Alleges Male Breast Growth Injuries Caused by Anti-Psychotic Medication, Bernstein Liebhard LLP Reports
5. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Settlement in Risperdal Marketing Investigation
6. Risperdal Lawsuits: $2.2 Billion Settlement Between Federal Government, Johnson & Johnson Over Alleged Illegal Marketing of Risperdal, Other Medications
7. Risperdal Lawsuit News: Johnson & Johnson To Pay Over $2.2 Billion In Risperdal and Invega Settlement Draws Comment From Wright & Schulte LLC
8. J&J to Pay $2.2B to Settle Allegations Over Its Marketing of Risperdal; Parker Waichman LLP Applauds Efforts of Whistleblowers in Helping Compel Resolution
9. Risperdal Lawsuit News: Rottenstein Law Group LLP Comments on $2 Billion Risperdal Settlement Report
10. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Mounting Claims Involving Risperdal Gynecomastia Allegations in Pennsylvania Litigation
11. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Release of Emails from Johnson & Johnson’s Janssen Subsidiary in Federal Risperdal Settlement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... TX (PRWEB) , ... July 27, 2017 , ... ... and outsourced services, announces the internal promotion of Elrene Clinkscales to Vice President ... – Claims & Remittance Management, reporting to Derek Morkel, chief executive officer (CEO). ...
(Date:7/27/2017)... ... July 27, 2017 , ... Team Novo Nordisk, the world’s first all-diabetes professional ... squad as a stagiaire for the remainder of the 2017 season. One of our ... at the Tour of Utah. , “Every season we are excited to move an ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... is pleased to now offer a major advancement in drug therapy for patients ... Ocrevus (pronounced Ah-creh-vus) is a novel B cell targeted therapy that has ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are dentists and we ... from San Jose, Calif., “so we invented the MAGNETIC/ LOCK BRACKETS.” , The patent-pending ... orthodontic braces. In doing so, it offers an effective alternative to traditional braces. As ...
(Date:7/26/2017)... Baton Rouge, Louisiana (PRWEB) , ... July 26, 2017 , ... ... their doctors to offer the ability for patients to schedule an appointment online in ... LocalMed directly from the Six Month Smiles provider directory will bring more Six Month ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... EXTON, Pa., July 27, 2017  West Pharmaceutical Services, ... financial results for the second-quarter 2017 and updated financial ... Second-Quarter 2017 Highlights Reported ... 2.5% over the prior-year quarter. Net sales at constant ... 2017 reported-diluted EPS was $0.51, compared to $0.60 in ...
(Date:7/26/2017)... NEW YORK , July 26, 2017 ... Annual Prix Galien USA Award ... honors, the Prix Galien Award recognizes outstanding biomedical and technology ... To qualify, each candidate must be ... the last five years and demonstrate tremendous potential to impact ...
(Date:7/24/2017)... 24, 2017  Diplomat Pharmacy, Inc. (NYSE: ... second quarter 2017 operating results on Monday, August 7, ... follow at 5:00 p.m. ET. ... a live broadcast of the conference call by dialing ... code 51641230 approximately 15 minutes prior to the call. ...
Breaking Medicine Technology: